TerrAscend at the ATB Capital Markets 2024 Life Sciences Conference

TerrAscend at the ATB Capital Markets 2024 Life Sciences Conference

Frankfurt (pta001/15.09.2024/08:00 UTC+2)

TerrAscend Corp. (ISIN: CA88105E1088), a North American cannabis organization, announced its management team at the ATB Capital Markets 2024 Life Sciences Institutional Investor Conference, September 18, 2024 in New York City, on September 18, 2024 in New York City.

The ATB Capital Markets 2024 Life Sciences Institutional Investor Conference is an important representation for investors and companies in the Life Sciences sector. They bring together institutional investors with financial institutions from the Life Sciences sector.

Jason Wild, Executive Chairman, will present a panel discussion on “Regulatory Ripples, Market Impacts: How Cannabis Reform Will Impact Valuations and Investor Engagement,” joined by Dan Ahrens, Chief Operating Officer of Advisor Shares, and moderated by Frederico Gomes, Director of Institutional Life Sciences Research at ATB Capital Markets, on Wednesday, September 18 at 8:00 a.m. ET.

Das Management, together with Herr Wild, Ziad Ghanem, Chief Executive Officer, and Keith Stauffer, Chief Financial Officer, were together with the Konferenz for the Einzelgespräche of the Verfügung Stehen.

———-

Would you like to stay regularly informed? Then you can read the Nebenwerte-Verteiler eintrage. Einfach an email to Eva Reuter [email protected] with the Stichwort “Nebenwerte”.

TerrainAscend 
ISIN code: CA88105E1088
https://terrascend.com/
Country: Canada

Disclaimer/Risk limitation 
Conflicts of interest: With TerrAscend there is an integrated IR and PR statement. If you activate the conscription, the level of the subdivisions is higher. Dr. Reuter Investor Relations dealt with the history and expansion of articles in the interest of TerrAscend. It is a question of a real editorial position. Actions of TerrAscend can be found in the Besitz van Mitarbeitern or Autoren of Dr. Reuter Investor Relations – an overview of the rules of the Market Abuse Regulation (MAR).

Business risks: Who is the best way to take risks in the area of ​​modeling the model. It is not that the design model makes the plans a lot more difficult. Further company risks of TerrAscend can be found on the page: https://terrascend.com/are mentioned.

Investment risks: No more investments are made now, but the research will no longer continue for the security of livelihood. It is not certain that an article from the previous century is worth using the time point. Grundsätzlich unterliegen Aktien under the risks of a total indulgence.

Disclaimer: All in this Newsletter / Article available Information available for further research. This information does not constitute a Verkaufsangebot for the discussed Action(s) nor an Aufforderung zum Kauf or Verkauf von Wertpaperen dar. The Ausführungen lie Quellen zgrunde, die der Herausgeber für trauenswürdig erachtet.

Sources: Particular attention has been paid to the information and analysis of the social information on the external website. As a rule, it is best to contact the Vorstand / IR Team of your analysis instruments bzw. vorgestellten Gesellschaft. The article would be a vorgelegt for the Veröffentlichung TerrAscend, a rifle scope for all types of welding work.

Future-oriented excursions 
This Mitteilung enthält bestimmte zkunftsgerichtte Aussagen, einschließlich Aussagen über das Unternehmen. We are always more than happy to know what we are talking about: we can understand it, are able to do it, solve it, know it, understand it, plan it, look at it, look at it, look forward to it, look forward to it, look forward to it and look forward to it or “potenziell” or the Verneinung or other Variationen die Wörter or ähnliche Wörter or Phrasen used, een diese zukunftsgerichteten Aussagen zu identifizieren. These findings reflect the authors’ personal insights more broadly and are based on information, which they author from the time of their publication.

Future-oriented exits are associated with real risks, uncertainties and uncertainties. Many factory settings can be carried out if the actual errors, achievements or failures are abwechen from the errors that are or were implied in the future-oriented exits. These factory towers will probably be tracked down, and the reader will no longer come to the future-oriented exits in an uncomplicated situation. If you get started with the authorization during the press conference on Annahmen, learning cannot be more certain, that the actual ones are very good with those future-oriented exits-overe-instimmen. Dr. Reuter Investor Relations is not obligated, these Aussagen are active or active, a new Ereignissen or Umstandden Rechnung of slow, so that there is no longer any question of writing.

Verantwortlich & Kontakt für Rückfragen 
Small & MicroCap investments through Dr. Reuters Investor Relations
Dr. Eva Reuter
Friedrich Ebert Annex 35-37
60327 Frankfurt
+49 (0) 69 1532 5857
www.dr-reuter.eu
www.small-microcap.eu

Für Fragen bitte Nachricht an [email protected]

About Dr. Reuter Investor Relations: Dr. Reuter Investor Relations is an Investor Relations Agentur / Investor Relations Agency offering the following services: Small Cap Investor Relations, Retail Investor Relations, Private Investment, Institutional Investor Relations, Institutional Investor Relations, Finanz-Public Relations, ESG Services, Roadshows, Investor Access, Capital Market Compliance, Equity Research.

(End)